|
Optimizing axitinib treatment selection following first-line sunitinib in metastatic renal cell carcinoma. |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Novartis |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Pfizer; Pierre Fabre |
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Novartis; Pfizer |
Research Funding - AstraZeneca; Bristol-Myers Squibb; Novartis; Pfizer; Roche; Sanofi |
Travel, Accommodations, Expenses - Novartis; Pfizer |
|
|
Honoraria - Ipsen; Pfizer |
Consulting or Advisory Role - Novartis; Pfizer |
Research Funding - Medac (Inst) |
Travel, Accommodations, Expenses - Medac; Pfizer |
|
|
Honoraria - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer |
|
|
Stock and Other Ownership Interests - Kite, a Gilead company |
Honoraria - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pfizer |
Speakers' Bureau - Merck Sharp & Dohme |
|
|
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Ipsen; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Novartis; Pfizer |
Speakers' Bureau - Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer |
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis; Pfizer (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Ipsen; Novartis; Pfizer; Roche/Genentech |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EUSA Pharma; Exelixis; Ipsen; Novartis; Pfizer |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer |